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Objectives: To explore the relationship between severity of pelvic organ prolapse (POP),
symptoms of pelvic dysfunction and quality of life using validated measures. Method: Baseline
data from 314 participants in the Colpopexy And Urinary Reduction Efforts (CARE) trial were
analyzed. Pelvic symptoms and impact were assessed using the Pelvic Floor Distress Inventory
(PFDI) and the Pelvic Floor Impact Questionnaire (PFIQ). PFDI and PFIQ scores were compared by
prolapse stage and history of incontinence or POP surgery. Regression analyses were performed to
identify other predictors of symptoms and impact. Results: Women were predominantly (90%)
Caucasian and had mean age of 61 years. Women with stage II POP, especially those with prior
surgery, reported more symptoms and impact than women with more advanced POP. There were
no other significant predictors of symptoms or life impact. Conclusions: Women planning
sacrocolpopexy with stage II prolapse and prior pelvic surgery reported more symptoms and
quality of life impact than those with more advanced prolapse.
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Table 1 Clinical and demographic characteristics of 314
women by stage of POP
POP stage Total p-value
II III IV
N 43 211 60 314
Age Mean 56 61 67 61 b0.001 a
Std
dev
12 10 8 10
Race
Caucasian 39 195 53 287 0.110 b, c
African American 0 10 6 16
Other 5 4 2 11
Ethnicity
Hispanic 0 8 1 9 0.520 b
Non-Hispanic 43 203 59 305
Prior surgery for
incontinence or POP
Yes 25 79 22 126 0.040 b
No 18 131 38 187
Number of
cesarean
deliveries
Mean 0.09 0.07 0.08 0.08 0.640 d
IQR 0–0 0–0 0–0 0–0
Number of
Vaginal
Deliveries
Mean 2.88 2.92 3.34 2.99 0.100 a
IQR 2–4 2–3 2–4 2–4
Menopausal status
Pre-menopausal 10 23 3 36
Post-menopausal 29 186 56 271
Not sure/missing 4 2 1 7
POP: pelvic organ prolapse.
IQR: interquartile range.
a One-way analysis of variance.
b Fisher's Exact test.
c White/Caucasian vs. Black/African American.
d Kruskal–Wallis test.
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Pelvic organ prolapse (POP) is common, with approximately
200,000 inpatient surgical procedures performed in the
United States annually for its treatment [1]. Many women
with POP experience pelvic symptoms including urinary,
colorectal and sexual dysfunction; however, others, includ-
ing some with advanced POP, report few such pelvic
symptoms.
Published studies of the relationship between prolapse
severity and pelvic symptoms demonstrate a relatively weak
relationship between those variables, but previous studies
have been limited by their retrospective nature and by their
use of poorly validated or unvalidated questionnaires. The
Colpopexy And Urinary Reduction Efforts (CARE) study is an
ongoing randomized clinical trial conducted by the Pelvic
Floor Disorders Network (PFDN) in which women with POP
but without symptoms of stress urinary incontinence under-
going abdominal sacrocolpopexy were randomly assigned to
either concomitant Burch or no Burch [2,3]. Prior to surgery,
participants completed several validated symptom and
quality of life measures, including the Pelvic Floor Distress
Inventory (PFDI) and the Pelvic Floor Impact Questionnaire
(PFIQ) [4].
The aim of this analysis was to explore the relationship
between severity of POP and symptoms of pelvic dysfunction
and quality of life using validated measures among women in
the CARE trial before surgery.
2. Materials and methods
The Pelvic Floor Disorders Network (PFDN) is a cooperative
network of investigators from participating clinical centers and a
Data Coordinating Center (DCC), supported by the National
Institute of Child Health and Human Development (NICHD). The
primary goal of the PFDN is to improve the level of knowledge
about pelvic floor disorders in women, including pelvic organ
prolapse, urinary incontinence and fecal incontinence. The CARE
protocol was approved by the Institutional Review Boards at all
clinical sites and the Data Coordinating Center, and all women
provided written informed consent before participating.
Prior to randomization and surgery, participants underwent a
standardized physical examination with assessment of POP
according to the Pelvic Organ Prolapse Quantification (POP-Q)
system [5]. POP severity was analyzed by POP-Q stage and by the
leading edge of prolapse in centimeters relative to the hymen. In
addition, participants completed assessments of generic health-
related and condition-specific quality of life (QOL), administered
by telephone by trained personnel from a central site. Pelvic
symptoms and their functional impact were assessed by two
validatedmeasures: the Pelvic Floor Distress Inventory (PFDI) and
the Pelvic Floor Impact Questionnaire (PFIQ) [4]. The PFDI is a 46-
item measure that yields three scale scores: Urinary Distress
Inventory (UDI, 28 items, score 0–300), Pelvic Organ Prolapse
Distress Inventory (POPDI, 16 items, score 0–300), and Colorectal-
Anal Distress Inventory (CRADI, 17 items, score 0–400). In
addition, items from each scale can generate three subscale
scores. The POPDI scale yields a general subscale (7 items, score
0–100), an anterior subscale (6 items, score 0–100) and a posterior
subscale (3 items, score 0–100). For each question in the PFDI,
respondents are asked whether they usually experience a givensymptom and, if so, how much it bothers them on a scale from 1
(not at all) to 4 (quite a bit). Higher scores indicate a higher level
of symptoms, either more numerous symptoms or more bother
related to symptoms.
The PFIQ focuses on specific activities of daily living and the
extent to which they are affected by bladder, bowel, and/or
pelvic symptoms. Three scales can be derived: the Incontinence
Impact Questionnaire (IIQ), the Colorectal-Anal Impact Ques-
tionnaire (CRAIQ), and the Pelvic Organ Prolapse Impact
Questionnaire (POPIQ), each with 31 items and scores from 0
to 400. Respondents are asked how their bladder, bowel, and/or
pelvic symptoms affect each of the activities on a scale from 1
(not at all) to 4 (quite a bit). Higher scores indicate greater
(worse) functional impact.
The participant's age, race, body mass index (BMI) and prior
incontinence or POP surgery (henceforth collectively referred to
as ‘pelvic surgery’) were thought a priori to be possible
important predictors of current pelvic symptoms and QOL.
Scores of the three primary subscales of the PFDI and PFIQ and
the component (general, anterior and posterior) scores of the
POPDI subscale were computed for each subject and stratified
by prolapse stage. Mann–Whitney–Wilcoxon tests were used to
compare scores between prolapse stages with stage II as the
Table 2 PFDI and PFIQ subscale scores by POP stage
N POPDI
(0–300)
p-
value a
POPIQ
(0–300)
p-
value a
POP stage
II
43 121 (72–182) 28 (4–127)
POP stage
III
211 85 (51–149) 0.026 21 (3–57) 0.070
POP stage
IV
60 111 (75–154) 0.449 20 (2–62) 0.160
CRADI
(0–400)
CRAIQ
(0–300)
POP stage
II
43 63 (31–155) 17 (0–83)
POP stage
III
211 50 (15–108) 0.027 4 (0–33) 0.020
POP stage
IV
60 51 (23–94) 0.124 9 (0–38) 0.170
UDI (0–300) IIQ (0–300)
POP stage
II
43 56 (36–86) 35 (10–85)
POP stage
III
211 47 (27–83) 0.433 26 (10–64) 0.310
POP stage
IV
60 60 (39–96) 0.436 41 (12–90) 0.650
Values represent median (interquartile range) scores.
PFDI: Pelvic Floor Distress Inventory.
PFIQ: Pelvic Floor Impact Questionnaire.
POP: Pelvic Organ Prolapse.
POPDI: Pelvic Organ Prolapse Distress Inventory.
POPIQ: Pelvic Organ Prolapse Impact Questionnaire.
CRADI: Colorecto-anal Distress Inventory.
CRAIQ: Colorecto-anal Impact Questionnaire.
UDI: Urinary Distress Inventory.
IIQ: Incontinence Impact Questionnaire.
a p-value represents the statistical significance of the diffe-
rence in score when subjects with stage II prolapse were
compared to subjects with prolapse stages III and IV (Mann–
Whitney test).
26 M.P. FitzGerald et al.reference group, stratified by history of prior surgery. As women
with stage II prolapse were significantly more likely to have had
pelvic surgery (58.1%) compared to women with stage III (37.6%)
and IV (36.7%) prolapse, stages III and IV were combined in some
analyses to examine the effect of prior pelvic surgery on
symptom and life impact scores. Generalized linear regression
models adjusting for age, race, and BMI were then fitted toTable 3 PFDI subscale POPDI scores by prolapse stage
General subscale
(range 0–100)
p-value a Ante
(rang
POP stage II (N=43) 57.1 (21.4–78.6) 25.0
POP stage III (N=210) 42.9 (25.0–64.3) 0.177 20.8
POP stage IV (N=60) 50.0 (32.1–71.4) 0.639 33.3
Table values represent median (interquartile range).
PFDI: Pelvic Floor Distress Inventory.
POPDI: Pelvic Organ Prolapse Distress Inventory.
POP: Pelvic Organ Prolapse.
a p-values represent statistical significance of difference in subsca
subjects with prolapse stages III and IV.examine the independent effects of collapsed POP stage
variable on each subscale of the PFDI and PFIQ among women
with and without prior pelvic surgery. An alpha level of 0.05 was
applied for all hypothesis testing and all analyses were
performed using SAS v9.1. Subjects without complete POP-Q or
PFDI/PFIQ data at baseline were excluded from these analyses.
3. Results
Baseline data from 314 CARE subjects were analyzed,
representing 97.5% of all CARE subjects randomized.
Table 1 details subjects' sociodemographic characteristics
and past medical/surgical history. Notably, 40% of women
had prior pelvic surgery, including 25 of 43 women (58.1%)
with stage II POP. Women with Stage II POP were significantly
younger than women with more advanced stages of POP.
As detailed in Table 2, women with stage II prolapse had
statistically significantly greater POPDI, CRADI and CRAIQ
scores than women with stage III POP (pb0.05); scores on the
POPIQ followed the same pattern but were only marginally
significant. Scores for women with stage IV POP were similar
to Stage II scores. Women in all three POP-Q stages reported
similar urinary symptoms (UDI) and urinary impact on daily
activities (IIQ). Notably, while women with stage II and IV
prolapse reported moderate levels of symptoms, the
reported level of impact on daily activities remained quite
low.
Table 3 details findings for the three prolapse subscales
generated by the PFDI (general, anterior and posterior). As
shown, a similar pattern of results was observed whereby
women with stage II prolapse reported higher scores than
women with more advanced prolapse.
Table 4 compares PFDI and PFIQ scores for women with
stage II versus stages III or IV prolapse by prior pelvic surgery.
Among women with prior surgery, women with stage II
prolapse reported significantly more prolapse symptoms
(POPDI) and marginally more impact (POPIQ) than women
with more advanced prolapse. This contrast between the two
groups is also statistically significant with respect to color-
ectal-anal symptoms (CRADI and CRAIQ) but not for urinary
complaints (UDI and IIQ). There are no significant differences
among women without prior pelvic surgery regardless of
prolapse severity for any of the subscales. This was
confirmed by regression models adjusting for age, BMI, and
race that were constructed for PFDI and PFIQ scores by prior
pelvic surgery. Among women with prior pelvic surgery,
POPDI (p=0.01), CRADI (pb0.001), and CRAIQ (pb0.003) allrior subscale
e 0–100)
p-value a Posterior subscale
(range 0–100)
p-value a
(8.3–50.0) 25.0 (8.3–91.7)
(4.2–54.2) 0.639 16.7 (0.0–33.3) 0.005
(10.4–58.3) 0.302 25.0 (0.0–37.5) 0.030
le score when subjects with stage II prolapse were compared to
Table 4 Comparison of scores from subjects with stage
II prolapse compared to those from subjects with stages
III or IV, by prior surgery for incontinence or POP
POP stage Score p-value a
Prior surgery
POPDI, range 0–300 II 156 (101–202) 0.004
III or IV 95 (54–158)
POPIQ, range 0–400 II 52 (8–144) 0.090
III or IV 25 (6–54)
CRADI, range 0–400 II 117 (58–188) b0.001
III or IV 48 (17–100)
CRAIQ, range 0–400 II 61 (4–135) 0.004
III or IV 5 (0–33)
UDI Range 0–300 II 68 (38–102) b0.300
III or IV 56 (33–90)
IIQ, range 0–400 II 43 (11–114) 0.200
III or IV 27 (11–58)
No prior surgery
POPDI, range 0–300 II 85 (44–121) 0.440
III or IV 88 (57–146)
POPIQ, range 0–400 II 23 (4–101) 0.500
III or IV 19 (0–67)
CRADI, range 0–400 II 30 (17–53) 0.200
III or IV 50 (17–105)
CRAIQ, range 0–400 II 4 (0–29) 0.970
III or IV 4 (0–34)
UDI, range 0–400 II 44 (36–67) 0.440
III or IV 48 (29–84)
IIQ, range 0–400 II 35 (10–54) 0.690
III or IV 32 (10–79)
Values represent median (interquartile range).
PFDI: Pelvic Floor Distress Inventory.
PFIQ: Pelvic Floor Impact Questionnaire.
POPDI: Pelvic Organ Prolapse Distress Inventory.
POPIQ: Pelvic Organ Prolapse Impact Questionnaire.
CRADI: Colorecto-anal Distress Inventory.
CRAIQ: Colorecto-anal Impact Questionnaire.
UDI: Urinary Distress Inventory.
IIQ: Incontinence Impact Questionnaire.
a p-value represents significance of the test for difference
between these scores when subjects with stage II prolapse were
compared to subjects with prolapse stages III or IV.
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women without prior pelvic surgery, symptoms and QOL did
not vary with POP stage.
When prolapse was analyzed by the position of the leading
edge of prolapse, rather than by POP stage, similar results
were found (data not shown).
4. Comment
The most important finding of this study is that a history of
pelvic surgery has a significant influence on the relationship
between the stage of POPand the severity of pelvic symptoms
and impact on quality of life.
Several observations can be made regarding women with
stage II prolapse and prior pelvic surgery, who are now
presenting for another surgical procedure for POP correction.
It may be that those women have a lower threshold fordiscomfort and diminished quality of life before they arewilling
to undergo further surgery, i.e. women who previously had
pelvic surgery may have different expectations and find
symptoms more bothersome if they persist or recur. Alterna-
tively, women with stage II POP may be more driven by the
presence of pelvic symptoms to undergo reoperation, i.e.,
patients with stage II POP planning abdominal sacrocolpopexy
maybeonly thosewith remarkable urinary andbowel symptoms
concurrent with their relatively mild prolapse. Women with
more advanced prolapse, with or without prior surgery, may be
driven by the physical presence of prolapse more than by the
bother and life impact of their other pelvic symptoms.
Finally, surgeon selection bias is likely to be present, since
by definition these are patients with lower stages of POP who
have been offered transabdominal prolapse repair. Specifi-
cally, it is likely that surgeons offer abdominal sacrocolpo-
pexy to women with stage II POP who have significant
symptoms and/or who have already had incontinence or POP
repair. It may be that women with stage II POP and mild
symptoms may be more likely to be offered transvaginal
repair and would not be CARE participants. It will be
especially interesting to observe these subjects with stage
II POP to determine whether preoperative symptoms and
bother resolve after surgery, or whether their symptoms
represent something that prolapse repair does not address.
Although patient and surgeon selection biases probably
explain much of our results, our findings do mirror those of
several other studies conducted in other patient populations,
that have demonstrated a relatively weak association
between pelvic symptoms and the stage of prolapse. For
example, Burrows et al. [6] found that patients with
incontinence (stress and urge) had less advanced prolapse.
Ellerkmann et al. [7] reported weak associations between
voiding difficulty and increasing severity of anterior and
apical prolapse, and between defecatory dysfunction,
incomplete evacuation, digital manipulation for defecation
and worsening posterior vaginal prolapse. Mouritsen [8] also
reported similarly weak correlations between prolapse
severity and all pelvic symptoms.
The weak association between PFDI/PFIQ scores and
prolapse severity may also be related to the fact that POP-
Q staging reflects only part of the clinical reality and cannot
fully represent the function of the pelvic floor, urinary, or
anorectal systems and the way in which symptoms impact
individual patients. In addition, since the PFDI and PFIQ
scales, during their initial validation in patients with stage III
and IV prolapse, showed only moderate correlations with
semi-quantitative measures of symptom severity such as
bladder and bowel diaries, it is possible that our current tools
cannot yet accurately reflect the most bothersome symp-
toms that patients experience in association with prolapse.
Our results further emphasize the need for clinicians to
assess the combination of clinical findings and symptom
experience to fully understand how women are affected by
pelvic floor dysfunction.
Strengths of this study include the large sample size,
standardized evaluation, and data collection by experienced
interviewers. Limitations include the lack of a control group
and the heterogeneity of the study population. More
homogeneous results might have been found in a study
population limited to women undergoing prolapse surgery for
the first time. However, study participants do represent a
28 M.P. FitzGerald et al.range of patients that clinicians encounter in their daily
practices. In lieu of a control group, postoperative findings
from this study population will be studied to learn more
about which preoperative symptoms resolve and which
persist, and may be useful in patient counseling.
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